Avadel Pharmaceuticals Enters Exclusive Global License Agreement With XWPharma To Develop and commercialize Valiloxybate For Indications Including Sleep Disorders; XWPharma To Receive $20M Upfront And Potential Milestones
Author: Benzinga Newsdesk | September 03, 2025 03:32pm